Physician profile
Mitchell Prywes
NPI 1538172861
$3,482.82
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $793 · 2021: $955 · 2022: $451.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,111.41 | 2019-2022 | |
| Abbvie INC. | $601.90 | 2019-2022 | |
| Ucb, INC. | $263.15 | 2019-2022 | |
| Lilly USA, LLC | $244.97 | 2019-2021 | |
| Celgene Corporation | $219.14 | 2019 | |
| Sobi, INC | $170.47 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $135.70 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $122.51 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $105.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $90.51 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $89.67 | 2020-2022 | |
| Pfizer INC. | $78.87 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $68.92 | 2021-2022 | |
| Janssen Biotech, INC. | $43.84 | 2019 | |
| Antares Pharma, INC. | $40.22 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.71 | 2019 | |
| Ibsa Pharma INC. | $22.97 | 2022 | |
| Janssen Scientific Affairs, LLC | $21.92 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $20.59 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Prywes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.